New EMA guidance to stress role of biology in cancer drug development
This article was originally published in Scrip
The European Medicines Agency is planning to update its guidance on evaluating anticancer drugs to take account of the increase in the growing number and increasing diversity of new substances being developed and the need to identify those patients most likely to respond to a particular product.
You may also be interested in...
In addition to our daily in-depth coverage of key events relating to the COVID-19 pandemic, we’re bringing you a periodic round-up of other developments. This edition covers Europe and other countries.
The US company is bringing extra supplies of lopinavir/ritonavir into France but stresses that the combination treatment is not authorized for treating patients with the coronavirus.
As part of its efforts to preserve patient access to medicines amid the COVID-19 pandemic, Russia is planning to cap drug prices if increases of more than 30% are detected. It will also allow online sales of non-prescription drugs and may also tighten the rules on fake and substandard products.